You searched for "litigation"

1616 results found

A focus on Pakistan’s growing eye care needs: over 43 million patients treated for curable blindness free of charge

With 90% of the world’s visually impaired living in developing countries, Pakistan is no exception to this on-going global healthcare challenge. Despite massive leaps over the last few decades in targeting this issue, the World Health Organisation (WHO) reports that...

Recurrent corneal erosions secondary to isotretinoin use

Isotretinoin (13–cis-retinoic acid) is the first line treatment for moderate to severe nodulocystic or papulopustular acne [1,2]. Although it is a safe medication, it has several adverse side-effects, including ophthalmic manifestations, as shown in Table 1 [3]. These side-effects need...

PACK-crosslinking for infectious keratitis

Corneal cross-linking with riboflavin and UV-A light (CXL) is a technology that has been initially developed to treat corneal ectatic disorders [1]. Its effect in stabilising diseases such as keratoconus was reported in numerous trials with excellent long-term outcomes and...

Corneal transplantation in the United Kingdom: are we blind to the challenges that still exist after the Organ Donation Bill?

Corneal transplantation (CT) is a significant treatment option for a huge number of patients in the United Kingdom (UK) [1]. For an individual, CT results in a substantial improvement in quality of life. Penetrating keratoplasty with full thickness grafting has...

Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals

Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...

Using OneNote in teams

Much like Outlook, Word, PowerPoint and Excel, OneNote is part of Microsoft Office. For this reason it is likely that you will have access to it in your work environment. Used in isolation it is an easy to use and...

SOS (Simplified Ophthalmic Statistics) Part 3: Which statistical test should I use (if any)?

P<0.05 is a statement that brings joy to many researchers. Arguably this is because inclusion of such a statement may increase the chance of acceptance for publication. Whilst statisticians and non-statisticians are united in trying to change this culture, cultural...

A tale of two membranes

It was the best of times, it was the worst of times... It was the season of Light, it was the season of Darkness... I am fortunate to work on a vitreoretinal firm at the moment and only a few...

Community Eyecare Services in Northern Ireland: putting the patient at the centre, improving outcomes and maximising system resource

The UK has four healthcare systems; Northern Ireland, Scotland and Wales each has autonomous legislature that develops health policy, while the UK government directly runs England’s NHS. Like the other nations, Northern Ireland is continually challenged to meet the needs...

Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments

Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...

The results of the last survey Feb21

Once again, I am grateful for the responses and read the results with interest. I am always surprised by the amount of practice variation I see. I fully accept there is art in what we do and there is no...

The results of the last survey Apr21

There was a really fascinating response to the last edition’s practice variance survey. Strictly speaking, I cheated and this was not really about practice variation, but more about your impressions about what represents negligent practice. For the first time ever,...